Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia

In BCR-ABL1 lymphoblastic leukemia, treatment heterogeneity to tyrosine kinase inhibitors (TKIs), especially in the absence of kinase domain mutations in BCR-ABL1, is poorly understood. Through deep molecular profiling, we uncovered three transcriptomic subtypes of BCR-ABL1 lymphoblastic leukemia, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jaeseung C., Chan-Seng-Yue, Michelle, Ge, Sabrina, Zeng, Andy G. X., Ng, Karen, Gan, Olga I., Garcia-Prat, Laura, Flores-Figueroa, Eugenia, Woo, Tristan, Zhang, Amy Xin Wei, Arruda, Andrea, Chithambaram, Shivapriya, Dobson, Stephanie M., Khoo, Amanda, Khan, Shahbaz, Ibrahimova, Narmin, George, Ann, Tierens, Anne, Hitzler, Johann, Kislinger, Thomas, Dick, John E., McPherson, John D., Minden, Mark D., Notta, Faiyaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335939/
https://www.ncbi.nlm.nih.gov/pubmed/37337105
http://dx.doi.org/10.1038/s41588-023-01429-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335939/
https://www.ncbi.nlm.nih.gov/pubmed/37337105
http://dx.doi.org/10.1038/s41588-023-01429-4

Ejemplares similares